Ftse Mib
35.398,82
-0,03%
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
NASDAQ
16.685,97
-0,07%
Bitcoin
66.991,10
-0,13%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni Canada CSE PharmaTher Holdings Ltd (PHRM) PharmaTher Holdings Ltd (PHRM) Notizie

PHRM

PharmaTher (PHRM)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:CSE:PHRM
DataOraFonteTitoloSimboloCompagnia
11/11/202116:00InvestorsHub NewsWirePharmaTher Announces Positive Research Results for Psilocybin Microneedle PatchCSE:PHRMPharmaTher Holdings Ltd
03/11/202113:03InvestorsHub NewsWirePharmaTher Enters into Research Collaboration Agreement with Revive Therapeutics for Development of Psilocybin Microneedle PatchCSE:PHRMPharmaTher Holdings Ltd
19/10/202113:07InvestorsHub NewsWirePharmaTher Engages Alcami for Clinical and Commercial Manufacturing of Novel Ketamine ProductsCSE:PHRMPharmaTher Holdings Ltd
13/10/202115:20InvestorsHub NewsWirePharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain SyndromeCSE:PHRMPharmaTher Holdings Ltd
21/09/202116:19InvestorsHub NewsWirePharmaTher Added to the North American Psychedelics Index and First Psychedelic Exchange Traded FundCSE:PHRMPharmaTher Holdings Ltd
13/09/202115:03InvestorsHub NewsWirePharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and 2022CSE:PHRMPharmaTher Holdings Ltd
04/08/202114:15InvestorsHub NewsWirePharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Amyotrophic Lateral SclerosisCSE:PHRMPharmaTher Holdings Ltd
21/07/202114:19InvestorsHub NewsWirePharmaTher Expands Psychedelic Patent Portfolio with Filing of U.S. Patent Application for Novel Ketamine FormulationCSE:PHRMPharmaTher Holdings Ltd
16/06/202117:14InvestorsHub NewsWirePharmaTher Files FDA Pre-IND Meeting Request and Briefing Package For KETABET™ To Treat DepressionCSE:PHRMPharmaTher Holdings Ltd
25/05/202114:45InvestorsHub NewsWirePharmaTher Files for FDA Orphan Drug Designation for Ketamine to Treat Lou Gehrig's DiseaseCSE:PHRMPharmaTher Holdings Ltd
17/05/202114:02InvestorsHub NewsWirePharmaTher Announces FDA Approval of Ketamine IND In The Treatment of Parkinson's DiseaseCSE:PHRMPharmaTher Holdings Ltd
27/04/202113:47InvestorsHub NewsWirePharmaTher Expands Patent Portfolio with Filing of U.S. Patent Application for Ketamine and Repurposing of Psychedelics..ContCSE:PHRMPharmaTher Holdings Ltd
20/04/202114:00InvestorsHub NewsWirePharmaTher Announces Submission of IND Application with the FDA for Phase 2 Clinical TrialCSE:PHRMPharmaTher Holdings Ltd
15/04/202117:32InvestorsHub NewsWirePharmaTher Provides Update on Psychedelic Product ProgramsCSE:PHRMPharmaTher Holdings Ltd
02/03/202113:34InvestorsHub NewsWirePharmaTher Expands to Neuromuscular Diseases with Exclusive License Agreement for Ketamine in the Treatment of Lou....ContCSE:PHRMPharmaTher Holdings Ltd
17/02/202116:11InvestorsHub NewsWirePharmaTher Announces Sale of Psilocybin ProgramCSE:PHRMPharmaTher Holdings Ltd
04/02/202114:21InvestorsHub NewsWirePharmaTher Announces Successful Completion of Pre-IND Meeting with FDACSE:PHRMPharmaTher Holdings Ltd
01/02/202114:19InvestorsHub NewsWirePharmaTher Signs Exclusive Worldwide License Agreement for Patented Microneedle Delivery Technology to Deliver KetamineCSE:PHRMPharmaTher Holdings Ltd
19/01/202114:07InvestorsHub NewsWirePharmaTher Signs Exclusive Worldwide License Agreement for Patented Ketamine FormulationCSE:PHRMPharmaTher Holdings Ltd
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:CSE:PHRM

La tua Cronologia

TSX
PRB
Probe Gold
NASDAQ
FTDYX
Franklin Moderate Alloca...
ASX
EMR
Emerald Resources NL
LATK
CRVBTC
Curve DAO Token
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network